Humacyte Inc Stock Price, News & Analysis

Humacyte (NASDAQ: HUMA) presented results from its V007 Pivotal Phase 3 clinical trial of ATEV (acellular tissue engineered vessel) at the Society for Vascular Surgery Meeting. The study compared ATEV to arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease requiring hemodialysis. The trial enrolled 242 patients, including 110 high-risk patients. Results showed ATEV demonstrated better functional patency and usability compared to AVFs in high-risk patients (women and men with BMI ≥30kg/m2 with diabetes). While ATEV showed more thrombosis and stenosis events than AVF, these were mostly treatable. The safety profile was comparable to AVF with similar infection rates, and ATEV patients required fewer maturation and surgical revision procedures. The study particularly benefits women and patients with obesity and diabetes, who represent over half the dialysis access market and historically face higher AVF maturation failure rates.

Humacyte announced that results from its V007 Pivotal Phase 3 clinical trial for its ATEV (acellular tissue engineered vessel) in arteriovenous access for high-risk dialysis patients will be presented at the Society for Vascular Surgery Vascular Annual Meeting (VAM25). The presentation, titled 'Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis,' suggests positive trial outcomes for HUMA's bioengineered vessel technology. Dr. Mohamad A. Hussain from Brigham and Women's Hospital and Harvard Medical School will present the findings on June 6, 2025, at 10:50 a.m. CT in New Orleans during Plenary Session 6.

Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at the Nasdaq World Headquarters in New York on May 20, 2025.

The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at 12:30 p.m. EST. Management will also be available for one-on-one meetings. A webcast replay will be accessible through the Events & Presentations section of Humacyte's website.

Humacyte (Nasdaq: HUMA) reported Q1 2025 financial results and key business updates. The company achieved a major milestone with the commercial launch of Symvess™, its bioengineered vascular tissue product, generating first commercial sales of $147,000. Total revenue was $517,000, including $370,000 from a research collaboration. The company completed a $46.7 million public offering and implemented cost reductions, including a workforce reduction of 31 employees, targeting savings of $13.8 million in 2025 and up to $38 million in 2026. Currently, 45 hospitals have initiated the Value Analysis Committee approval process for Symvess, representing about 25% of all Level 1 trauma centers. The company reported net income of $39.1 million for Q1 2025, compared to a net loss of $31.9 million in Q1 2024, primarily due to non-cash remeasurement of contingent earnout liability. Cash position stood at $113.2 million as of March 31, 2025.

Humacyte (NASDAQ: HUMA), a clinical-stage biotechnology company focused on developing universally implantable, bioengineered human tissue, has scheduled its Q1 2025 financial results release and corporate update for May 13, 2025. The company will host a conference call and webcast at 8:30 AM ET.

U.S. investors can join via 1-877-704-4453, while international participants can dial 1-201-389-0920 using conference ID 13753487. The webcast will be available 15 minutes before the call and remain accessible on the company's investor relations website for at least 30 days afterward.

Humacyte (NASDAQ: HUMA) announced its Q4 and full-year 2024 financial results, highlighting the FDA approval of Symvess™ for extremity vascular trauma treatment in December 2024. The company has initiated commercial launch with first sales in February 2025, with 34 hospitals starting the Value Analysis Committee approval process and three hospitals already approving purchases.

Financial highlights show no revenue for Q4 and full-year 2024. R&D expenses were $20.7M in Q4 2024 and $88.6M for the full year. Net loss increased to $148.7M for 2024, compared to $110.8M in 2023. The company reported $95.3M in cash and equivalents as of December 31, 2024, with an additional $46.6M raised through a public offering in March 2025.

Key developments include positive Phase 3 trial results for arteriovenous access in dialysis patients, plans for a supplemental BLA submission in H2 2026, and an upcoming IND filing in 2025 for coronary artery bypass grafting studies.

Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale, has scheduled its Q4 and full-year 2024 financial results release for March 28, 2025.

The company will host a webcast and conference call at 8:30 a.m. ET on the same day. The webcast will be available 15 minutes before the call begins, and a replay will be accessible on the company's investor relations website for at least 30 days following the broadcast.

Humacyte (Nasdaq: HUMA) has announced the pricing of a public offering of 25,000,000 shares of common stock at $2.00 per share, expecting to raise gross proceeds of $50 million. The offering is set to close around March 27, 2025.

The company has granted underwriters a 30-day option to purchase up to an additional 3,750,000 shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers.

The net proceeds will be used to fund the commercialization of SYMVESS™ in vascular trauma indication, development of product candidates in Humacyte's pipeline, and for working capital and general corporate purposes.

Humacyte (Nasdaq: HUMA) has announced an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase up to an additional 15% of offered shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company act as lead managers.

The commercial-stage biotechnology platform company, focused on developing universally implantable bioengineered human tissues, intends to use the proceeds to fund:

• Commercialization of SYMVESS™ in vascular trauma indication
• Development of product candidates in pipeline
• Working capital and general corporate purposes

The offering will be made through a shelf registration statement previously filed and declared effective by the SEC. The final size, terms, and completion of the offering remain subject to market conditions.